Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinco Pharmaceutical Holdings Ltd stock PB Ratio (=0.42) is close to 10-year low of 0.42.
The historical rank and industry rank for Sinco Pharmaceutical Holdings's PB Ratio or its related term are showing as below:
HKSE:06833'
s PB Ratio Range Over the Past 10 Years
Min: 0.42 Med: 1.7 Max: 31.25
Current: 0.44
During the past 12 years, Sinco Pharmaceutical Holdings's highest PB Ratio was 31.25. The lowest was 0.42. And the median was 1.70.
HKSE:06833's PB Ratio is ranked better than 92.04% of 113
companies
in the Medical Distribution industry
Industry Median: 1.07
vs HKSE:06833: 0.44
During the past 12 months, Sinco Pharmaceutical Holdings's average Book Value Per Share Growth Rate was 8.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 4.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 22.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 12.90% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Sinco Pharmaceutical Holdings was 148.30% per year. The lowest was -56.50% per year. And the median was 12.40% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Sinco Pharmaceutical Holdings PB Ratio Related Terms
Sinco Pharmaceutical Holdings PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sinco Pharmaceutical Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinco Pharmaceutical Holdings PB Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinco Pharmaceutical Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Sinco Pharmaceutical Holdings's PB Ratio falls into.
Sinco Pharmaceutical Holdings PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Sinco Pharmaceutical Holdings (HKSE:06833) has a PB Ratio of 0.44 as of Aug. 28, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sinco Pharmaceutical Holdings and its competitors. This is 74% below median its historical median of 1.70. Over the past decade, Sinco Pharmaceutical Holdings' PB Ratio has ranged from 0.42 to 31.25. According to the industry distribution chart, Sinco Pharmaceutical Holdings ranks #9 out of 113 companies in the Medical Distribution industry, placing it in the top 8%.
Is Sinco Pharmaceutical Holdings' PB Ratio too high?
Sinco Pharmaceutical Holdings' current PB Ratio of 0.44 is 74% below median its 10-year median of 1.70. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 31.25. The Medical Distribution industry median PB Ratio is 1.07. Sinco Pharmaceutical Holdings' value of 0.44 is 58.9% below this industry median. Based on the distribution chart, Sinco Pharmaceutical Holdings ranks #9 out of 113 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sinco Pharmaceutical Holdings has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinco Pharmaceutical Holdings' PB Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinco Pharmaceutical Holdings ranks #9 out of 113 companies for PB Ratio. This places Sinco Pharmaceutical Holdings in the top 8% of its industry — outperforming the majority of peers. The industry median PB Ratio is 1.07. Sinco Pharmaceutical Holdings' value of 0.44 is 58.9% below this benchmark. Historically, Sinco Pharmaceutical Holdings' own PB Ratio has ranged from 0.42 to 31.25 over the past decade. While the company's 10-year median is 1.70 vs. the industry median of 1.07, Sinco Pharmaceutical Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Distribution company?
The median PB Ratio among Medical Distribution companies is 1.07, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinco Pharmaceutical Holdings's current PB Ratio of 0.44 is 58.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Sinco Pharmaceutical Holdings and its competitors. For the Medical Distribution industry, the median PB Ratio is 1.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinco Pharmaceutical Holdings's current PB Ratio is 0.44, which is 74% below median its own 10-year median of 1.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinco Pharmaceutical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Sinco Pharmaceutical Holdings (HKSE:06833) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.19, compared to a current price of HK$0.17 — trading 12.6% below its estimated fair value. The current PB Ratio is 0.44, which is 74% below median its 10-year median of 1.70 and 58.9% below the Medical Distribution industry median of 1.07. Sinco Pharmaceutical Holdings' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Sinco Pharmaceutical Holdings (HKSE:06833), the current PB Ratio is 0.44 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinco Pharmaceutical Holdings (HKSE:06833) Overvalued in 2026?
Based on GuruFocus' analysis, Sinco Pharmaceutical Holdings stock appears to be undervalued.
The current stock price of HK$0.17 is trading 12.6% below its estimated GF Value™ of HK$0.19.
GuruFocus considers Sinco Pharmaceutical Holdings to be Modestly Undervalued.
Key valuation signals for HKSE:06833:
PB Ratio: 0.44 (74% below median its 10-year median of 1.70)
GF Value™: HK$0.19 vs. price of HK$0.17 (12.6% below fair value)
Industry Position: 58.9% below the Medical Distribution median (#9 of 113)
No single metric tells the full story. See the HKSE:06833 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinco Pharmaceutical Holdings Ltd is an investment holding company that deals in marketing, promotion, and channel management of improved human plasma-based pharmaceuticals, antibiotics, and other pharmaceuticals. The company operates in three business segments, namely biologics, medical aesthetic products, and biopharmaceutical cold chain and supply chain services. The biologics business provides marketing, promotion, and channel management services, while the medical aesthetic products business focuses on research and development, production, and sales of aesthetic medicine in China. The biopharmaceutical cold chain and supply chain services concentrate on the construction of cold chain facilities for biopharmaceutical products and establishing the supply chain service platform.
44GF Score
Get the complete analysis for HKSE:06833
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06833 has been successfully added to your 
